You are right, plenty of cash at bank (worst case scenario 4.5mil), cash flow positive last quarter without capital raises, still holds the patents for a successful drug whose testing is funded by one of the largest pharmaceutical companies on the NASDAQ and not an unexpected set back in manufacturing given the nature of biotech trials. Currently trading close to what some shells with less cash are valued at, should see a recovery to at least 1c in the short term, as the last of the weaker hands are cleaned out.
Longer term, it will depend on what the management does, and could indeed take a long time to play out, but short term, even for a trade, 0.6c was a no brainer for me.
PAB Price at posting:
0.8¢ Sentiment: Buy Disclosure: Held
